TCW Group Inc. Sells 21,344 Shares of DexCom, Inc. (NASDAQ:DXCM)

TCW Group Inc. lowered its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 2.4% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 850,134 shares of the medical device company's stock after selling 21,344 shares during the quarter. TCW Group Inc. owned approximately 0.22% of DexCom worth $56,993,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Blue Whale Capital LLP grew its holdings in DexCom by 91.9% during the third quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company's stock valued at $15,821,000 after purchasing an additional 113,000 shares during the period. Taylor Frigon Capital Management LLC grew its stake in shares of DexCom by 51.6% during the 3rd quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company's stock worth $2,182,000 after acquiring an additional 11,075 shares during the period. Brooktree Capital Management purchased a new stake in DexCom in the 3rd quarter worth about $683,000. National Pension Service lifted its holdings in DexCom by 4.1% during the third quarter. National Pension Service now owns 949,743 shares of the medical device company's stock valued at $63,671,000 after purchasing an additional 37,363 shares during the last quarter. Finally, Intact Investment Management Inc. bought a new position in DexCom during the third quarter worth about $650,000. Hedge funds and other institutional investors own 97.75% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Raymond James lowered their price target on shares of DexCom from $115.00 to $99.00 and set a "strong-buy" rating on the stock in a research report on Friday, October 25th. Leerink Partners dropped their target price on DexCom from $90.00 to $87.00 and set an "outperform" rating on the stock in a research report on Friday, October 25th. Oppenheimer dropped their price objective on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a report on Friday, October 25th. JPMorgan Chase & Co. lifted their target price on DexCom from $75.00 to $85.00 and gave the company a "neutral" rating in a report on Friday, October 25th. Finally, Sanford C. Bernstein raised their price objective on shares of DexCom from $82.00 to $86.00 and gave the company an "outperform" rating in a research report on Friday, October 25th. Seven analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $98.00.

DexCom Trading Up 1.3 %

NASDAQ DXCM traded up $1.06 during trading on Wednesday, hitting $80.47. 2,912,678 shares of the company's stock traded hands, compared to its average volume of 3,891,305. The firm has a market cap of $31.43 billion, a P/E ratio of 48.17, a PEG ratio of 2.38 and a beta of 1.12. The stock has a fifty day moving average of $72.77 and a two-hundred day moving average of $85.41. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of the company's stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now directly owns 71,192 shares of the company's stock, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.30% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.